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Abstract. – OBJECTIVE: More than a decade 
after e-cigarette (e-cig) market launch, limited 
information are available on their safety after 24 
months of use. In 2013, we started the first ob-
servational study assessing e-cig long-term ef-
fectiveness and safety, directly comparing to-
bacco smokers and e-cig users. Here we report 
the results after four years of follow-up.
PATIENTS AND METHODS: Adults (30-75 
years) were included if: smokers of ≥1 tobacco 
cigarette/day (tobacco smokers); users of any 
type of e-cig inhaling ≥50 puffs weekly (e-cig 
users); users of both tobacco and e-cig (dual 
users). Data were collected by phone and/or 
internet, and carbon monoxide levels tested 
in 50% of those declaring tobacco abstinence. 
Main outcomes were: possibly smoking-relat-
ed diseases (PSRD; validated through hospital 
discharge data or visit in 62.6% of the sample); 
4-year tobacco abstinence; number of tobacco 
cigarettes/day.
RESULTS: Data were available for 228 e-cig 
users (all ex-smokers), 471 tobacco smokers, 
216 dual users. A PSRD was observed in 73 
subjects (8.0%). No differences emerged across 
groups in PSRD rates, with negligible variations 
in self-reported health. Of e-cig users, 63.6% 
remained tobacco abstinent; dual users and 
tobacco smokers showed non-significantly dif-
ferent rates of tobacco (33.8% vs. 26.8%) and 
all-product (20.2% vs. 19.4%) cessation, and a 
similar decrease in cigarettes/day. Almost 40% 
of the sample switched at least once (tobacco 
smokers: 17.2%; dual users: 81.9%).
CONCLUSIONS: After four years, a scarce, 
non-significant harm reduction was observed 
among e-cig or dual users. Given the long-last-
ing health effects of tobacco smoking, the bene-
fits of e-cig use may start being detectable at the 
next follow-up (six years). The complete switch 
to e-cig may help tobacco quitters remain ab-
stinent, but e-cig use in addition to tobacco did 
not increase the likelihood of smoking cessa-
tion or reduction. 
Key Words
Electronic cigarettes, Electronic nicotine delivery 
devices, Smoking cessation, Harm reduction, Tobac-
co smoking.
Introduction
More than a decade after their launch on the 
market, e-cigarettes (e-cig) are still at the centre 
of a vast debate1-3. Although their use increased 
in the last few years, with tens of millions of 
regular vapers in EU and USA4-6, and in spite of 
the universal consensus on the need for additional 
safety data to support public health policies2,7-18, 
the available evidence on e-cig efficacy and safety 
is still inconclusive19,20. The information available 
on long-term e-cig safety is limited to nine healthy 
vapers, non-former smokers, who were followed 
for 3.5 years21, and scarce data are available on 
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e-cig patterns of use over time19,22. Moreover, 
although a recent, large trial reported a marginal 
efficacy of e-cigarettes as smoking cessation aids 
among a general population of unselected smok-
ers23, the few other available randomized trials24-27 
and the observational studies7-13,18,28-31 reported 
conflicting results10,19. In 2013, we started the only 
observational longitudinal study aimed at evaluat-
ing e-cigarette long-term effectiveness and safety 
through a direct comparison between the users of 
tobacco and electronic cigarettes, collecting health 
outcomes for more than 24 months32. The results 
of the 12- and 24-month follow-ups have been 
published previously33,34; here we report the main 
findings of the 4-year follow-up.
Patients and Methods
Patients
A detailed description of the study methodol-
ogy has been reported32,34, and it is also available 
on Clinicaltrials.gov (NCT01785537). Briefly, we 
recruited adults (30-75 years) who were: (a) smok-
ers of ≥ 1 tobacco (only) cigarette daily for ≥ 6 
months (tobacco smokers); (b) users of any type 
of e-cig for ≥ 6 months (e-cig users); (c) users of 
both tobacco and e-cig for ≥ 6 months (dual users). 
Potential participants were recruited via general 
practitioners, e-cig shops, internet advertisements, 
and social networks. Data were collected through 
a structured questionnaire, administered through a 
phone interview and/or by internet. Two investiga-
tors (MEF and LM) tested carbon monoxide levels 
in expired breath (Smokerlyzer® piCO+ ™, Bedfont 
Scientific Ltd.) in a random sample of 50% of the 
subjects declaring tobacco smoking abstinence. The 
follow-up will continue up to 72 months. Effec-
tiveness outcomes were: (a) the rate of quitting of 
all products (either tobacco and/or e-cig, for >30 
days); (b) the rate of abstinence/cessation from 
tobacco smoking at 48 months; and (c) the change 
in the daily number of tobacco cigarettes. Health 
outcomes were: (a) the rate of possibly smoking-re-
lated diseases; and (b) the change in self-reported 
health (assessed through the final item of the Italian 
version of the EuroQol EQ-D5L35,36). The follow-
ing diseases occurred during the 4-year follow-up 
were considered as “possibly smoking-related dis-
eases” (PSRD): chronic obstructive pulmonary dis-
ease (COPD), myocardial infarction and/or angina, 
congestive heart failure, transitory cerebrovascular 
ischemia or stroke, any cancer. Additional informa-
tion was requested on allergies and/or mouth irrita-
tion, which were considered separately from other 
safety outcomes. Health data were both self-report-
ed and obtained from direct visits (for the residents 
in Sicily - 16.0% of the sample) or hospital discharge 
abstracts (for the residents in the Abruzzo Region - 
46.6%). The last data collection was performed for 
all participants after 48±3 months since enrollment.
Data Analysis
In long, “real-life” studies, both the exposure 
– smoking status – and the main effectiveness 
outcome – quitting – change over time in a 
considerable proportion of participants37,38. As a 
consequence, the analyses based upon baseline 
status, which are similar to an Intention-to-treat 
approach (ITT, typically the best approach for 
randomized trials with stable final outcomes 
and group switching rate rarely exceeding 10%), 
should be complemented with analyses based 
upon “real-life” group assignments. Therefore, 
since this is an observational analysis aimed at 
providing real-life information after 4 years, we 
did not follow a strict ITT approach and did not 
include in the analyses the participants who did 
not provide any data at any follow-up assessment. 
Instead, three approaches were used for the anal-
yses, with a decreasing similarity with ITT:
A1 The exposure group (e-cig, dual user or to-
bacco only smoker) was assigned based upon 
the baseline smoking/vaping status (regardless 
of switching), and the analyses included all 
subjects that provided some data at the first 
follow-up visit (12 months – n=959). This an-
alytical approach was used for the evaluation 
of both categorical outcomes of effectiveness 
(quit all products and quit tobacco).
A2 The exposure group was assigned based upon 
the baseline smoking/vaping status (regardless 
of switching), and the analyses included only 
those who were followed up to 48 months 
(n=915). Notably, no PSRD were observed in 
previous 12- and 24-month assessments among 
the 44 subjects that were lost to follow-up at 24 
or 48 months. This second analytical approach 
was used for the evaluation of all outcomes.
A3 The exposure group was assigned based upon 
the baseline smoking/vaping status, and the 
analyses included only those subjects who were 
followed up to 48 months and never switched 
smoking/vaping status during the follow-up 
(“quitting” was not considered a switch). This 
analytical approach was used for the evaluation 
of both the continuous outcome of the effective-
ness and the safety outcomes. Multivariate ran-
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dom-effect linear and logistic regressions39,40, 
with geographical region as the cluster unit, 
were used to investigate potential predictors 
of continuous and categorical outcomes, re-
spectively. Multivariate models were set three 
times, one for each of the above three analytical 
approaches. The models predicting effective-
ness outcomes were adjusted for the following 
baseline characteristics, all included a priori 
into the model regardless of significance: age, 
gender, BMI, marital status, educational level, 
occupation, alcohol use, hypertension, hyper-
cholesterolemia, diabetes mellitus, self-rated 
health, smoking/vaping amount, and years of 
tobacco smoking. To reduce overfitting, the 
models predicting health outcomes were ad-
justed only for age, gender, self-rated health, 
years of tobacco smoking, and hypertension 
(all of which showed a p-value <0.2). Missing 
data were very few for all variables (<1%); no 
missing data imputation technique was thus 
adopted. A two-tailed p-value of 0.05 was 
considered significant for all analyses, which 
were performed using Stata 13.1 (Stata Corp., 
College Station, TX, USA, 2014).
Results
The flow of the participants is shown in the 
Additional Figure 1: 959 of the 1355 enrolled 
subjects provided data at least once (70.8%) and 
formed the sample of the analytical approach A1. 
After 4 years, data were available for 228 subjects 
that were e-cigarette only users at baseline, 471 
tobacco only smokers, and 216 dual users, for 
a total of 915 subjects (48.4 years on average, 
56.3% males). The latter sample, who completed 
the 48-month follow-up, was used for the analyt-
ical approaches A2 and A3. 
Health Outcomes
A PSRD was observed in 73 subjects (8.0%), 
with no significant differences across baseline 
groups: 7.9% PSRD were observed among base-
line e-cig users, 6.8% among tobacco smokers, 
and 10.7% among dual users (Table I, analytical 
approach A2). The results were similar when 
the analyses were restricted to the non-switchers 
(Table I, A3). No significant differences were 
also observed when only cancers (n=33 overall), 
or mouth irritation (n=41) were considered, both 
Table I. Rates of possibly smoking-related diseasesψ during the follow-up.
ψChronic obstructive pulmonary disease (COPD), myocardial infarction and/or angina, congestive heart failure, transitory 
cerebrovascular ischemia or stroke, any cancer.
All p-values for the comparisons between groups were not significant: they were thus not shown. 
  E-cig. Tobacco cig. Dual use
  % (n/N) % (n/N) % (n/N)
Any possibly smoking-related disease   
A2. Analyses by baseline status, including only the participants 7.9 (18/228) 6.8 (32/471) 10.7 (23/216) 
  with 4-year follow-up data 
A3. Analyses restricted to non switchers only, with all data 8.1 (10/123) 7.1 (29/409) 7.7 (3/39)
 at 48 months
Analyses further restricted to the participants with a visit 
 or hospital discharge data available   
A2.  8.2 (17/208) 10.5 (21/200) 12.8 (21/164)
A3.  7.8 (9/115) 12.3 (19/154) 10.7 (3/28)
Cancer only
A2.  4.4 (10/228) 3.4 (16/471) 3.2 (7/216)
A3.  4.9 (6/123) 3.4 (14/409) 2.6 (1/39)
Analyses further restricted to the participants with a visit 
 or hospital discharge data available   
A2.  4.3 (9/208) 6.0 (12/200 3.7 (6/164)
A3.  4.3 (5/115) 7.1 (11/154) 3.6 (1/28)
Mouth irritation   
A2.  6.1 (14/228) 4.5 (21/471) 2.8 (6/216)
A3.  6.5 (8/123) 3.7 (15/409) 0.0 (0/39)
Self-rated health - Mean difference baseline-4 years Mean (SD) Mean (SD) Mean (SD)
A2.  -0.3 (1.5) -0.2 (1.4) 0.0 (1.6)
A3.  -0.3 (1.5) -0.1 (1.3) +0.2 (1.4)
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in the complete and restricted sample. Also, a 
very small variation in self-reported health was 
observed over time and across groups (Table 
I). When the analyses were repeated including 
only the 297 participants who did not switch 
smoking/vaping group, and that were visited or 
had their outcomes confirmed through a linkage 
with hospital discharge abstracts, the rates of 
PSRD or cancer were lower among e-cig or dual 
users, as compared with tobacco smokers, but 
the differences were still non significant (Table 
I). Multivariate analyses were in line with uni-
variate results (Table II), with the exception of a 
significantly lower decrease – although clinically 
negligible – in self-reported health among e-cig 
users, as compared to tobacco smokers (Table II).
Outcomes of Effectiveness
After 4 years, 63.6% of the 228 baseline e-cig 
users were still abstinent from tobacco smoking; 
26.8% of the 471 baseline tobacco smokers and 
33.8% of the 216 baseline dual users achieved 
tobacco abstinence (p<0.05 for all differences 
across groups; Table III, analytical approach A2). 
The proportion of subjects who achieved com-
plete abstinence (were not using either tobacco 
cigarettes or e-cigarettes) did not significantly 
differ by baseline group: 23.7%, 20.2% and 19.4% 
among e-cig users, tobacco smokers and dual 
users, respectively (all p>0.05; Table III, A2). 
The results of both outcomes were similar when 
the 12-month larger sample was used (Table III, 
A1). During the follow-up, both baseline dual 
users and tobacco smokers showed a significant 
decrease in the mean number of tobacco ciga-
rettes smoked per day, but the reduction was only 
marginally higher among dual users (-4.9 vs. -4.3, 
respectively; Table III, A2). When the analyses 
were restricted to those who did not switch (Table 
III, A3), a large and significantly higher decrease 
in the number of tobacco cigarettes smoked per 
day was observed among dual users (vs. tobacco 
smokers; p<0.001). All univariate results were 
confirmed by the multivariate analyses (after 
adjusting for age, gender, BMI, marital status, 
educational level, occupation, alcohol use, hyper-
tension, hypercholesterolemia, diabetes, self-rat-
ed health, smoking amount and years of tobac-
co smoking), with one important exception: as 
compared to tobacco smokers, dual users did not 
Table II. Multivariate analyses on possibly smoking-related diseases and self-reported health.
AMultivariate random-effect logistic regression, with geographical region as the cluster unit, adjusted for baseline age, gender, 
self-rated health, years of tobacco smoking and hypertension.
BMultivariate random-effect linear regression, with geographical region as the cluster unit, adjusted for baseline age, gender, 
BMI, marital status, educational level, occupation, alcohol use, hypertension, hypercholesterolemia, diabetes, self-rated health, 
smoking/vaping amount, and years of tobacco smoking.
Outcomes Adjusted OR pA
 (95% CI)
Possibly smoking-related disease  
A2. Analyses by baseline status, including only the participants 
 with 4-year follow-up data  
- Tobacco smokers (ref. cat.) 1 (--) --
- E-cig. users 1.01 (0.52-1.98) 0.9
- Dual users 1.57 (0.84-2.96) 0.16
A3. Analyses restricted to non switchers only, with all data at 48 months  
- Tobacco smokers (ref. cat.) 1 (--) --
- E-cig. users 0.95 (0.41-2.22) 0.9
- Dual users 1.31 (0.34-5.04) 0.7
Self-rated health score
Difference baseline-4 years Adj. coefficient (95% CI) p
B
A2. Analyses by baseline status, including only the participants with 4-year follow-up data  
- Tobacco smokers (ref. cat.) 0 (--) --
- E-cig. users -0.28 (-0.48; -0.08) 0.007
- Dual users 0.18 (-0.02; 0.39) 0.08
A3. Analyses restricted to non switchers only, with all data at 48 months  
- Tobacco smokers (ref. cat.) 0 (--) --
- E-cig. users -0.34 (-0.65; -0.04) 0.028
- Dual users 0.45 (-0.13; 1.04) 0.13
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show a significantly higher probability of tobacco 
smoking cessation (p≤0.10; Table IV).
Switching Smoking/Vaping Status, 
and Pathway of Use Through
the Follow-Up
We defined “switchers” those who changed 
their exposure status (e.g., from e-cig only to dual 
use) at least once during the follow-up. Quitting 
all products was not considered switching, as this 
is an outcome of effectiveness. The smoking/va-
ping pathways of all participants throughout the 
follow-up, including switching category (yes or 
no), are reported in the additional Figure 2. A 
large number of participants switched during the 
4-year follow-up (37.7% of the overall sample), 
with wide differences across groups: 17.2% of 
tobacco smokers; 46.1% of e-cig users; and 81.9% 
of dual users. Such a pattern implies that, on one 
side, the analyses restricted to those who never 
switched were based upon a limited number of 
e-cig users (n=123) and dual users (n=39), and the 
results are complex to interpret (Tables III and IV, 
analytical approach A3). On the other side, some 
interesting data can be obtained from the analysis 
of participants’ pathways: e.g., the most common 
switching patterns or the rate of quitting failures. 
Of the 324 subjects who switched smoking/vap-
ing group at the 12- or 24-month assessments, 
29.9% (n=91) switched group again during the 
follow-up. Among the 63 baseline tobacco smok-
ers who changed status, 47 initially switched to 
e-cig use only. Of them, 30 were able to remain 
abstinent from tobacco, while 17 switched back 
to tobacco or dual use. Among the 105 base-
line e-cig users who changed status, 72 initially 
switched to tobacco smoking only. After this 
switch, only 10 subjects made a further attempt 
to cease tobacco. Among the 177 baseline dual 
users who changed status, 141 initially switched 
to tobacco smoking only (114 of them switched 
after 12 months of follow-up). After this switch, 
only a minority (n=23) made a further attempt to 
stop smoking. As regards the rate of quitting (of 
all products) failures, the proportion of subjects 
that were able to maintain abstinence after a quit 
attempt at the 12- or 24-month follow-up assess-
ments were:
Table III. Cigarette use after four years of follow-up.
*p-values that were significant at univariate analyses (using chi-squared test for categorical variables; t-test for continuous ones). 
If not reported, p-values are >0.05. 
AE-cig. only vs. tobacco cig. only.
BE-cig. only vs. dual use.
CTobacco cig. only vs. dual use.
  E-cig. Tobacco cig. Dual use p *
  % (n/N) % (n/N) % (n/N) 
Quitting any product 
(tobacco and/or e-cigarettes)    
A1. Analyses by baseline status, including  24.1  20.0 18.5
 the larger 12-month sample (57/236) (98/491) (43/232) 
A2. Analyses by baseline status, 23.7  20.2  19.4
 including only the participants (54/228) (95/471) (42/216) 
 with 4-year follow-up data 
Continuous tobacco abstinence from baseline 
or cessation from tobacco during follow-up    
A1. Analyses by baseline status, including 64.0 26.3 32.3 <0.001A; <0.001B;
 the larger 12-month sample (151/236)  (129/491) (75/232)  0.03C 
A2.  Analyses by baseline status, including only  63.6  26.8 33.8 <0.001A; <0.001B;
 the participants with 4-year follow-up data (145/228) (126/471) (73/216)  0.03C
Number of tobacco cigarettes per day -  Mean (SD) Mean (SD) Mean (SD)
Mean difference 4y-baseline     
A2. Analyses by baseline status, including only – -4.3 (8.5) -4.9 (11.2) 
  the participants with 4-year follow-up data 
A3. Analyses restricted to non switchers only,  – -3.3 (7.9) -10.2 (11.7) <0.001C
 with all data at 48 months 
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– 67.6% (71/105) among those who quit from 
tobacco smoking only;
– 94.1% (16/17) among those who quit from 
e-cig use only;
– 61.8% (21/34) among those who quit from dual use.
Overall, 496 subjects used e-cig at least once 
during the follow-up (including both e-cig users 
and dual users at baseline, and those who were 
tobacco smokers at baseline and then switched 
to e-cig or dual use during the follow-up). Of 
them, 99 (20.0%) were able to quit the use of 
all products. A similar quitting rate (21.7%) was 
observed among the 419 subjects who never used 
e-cig during the follow-up. Thus, even when the 
switching pattern was kept into account, the use 
of e-cig, either alone or in combination with 
tobacco cigarettes, did not seem to substantially 
enhance the propensity to quit.
Table IV. Multivariate analyses predicting tobacco and/or e-cig use abstinence and/or cessation, and the difference in the daily 
number of tobacco cigarettes smoked between year 4 and baseline.
AMultivariate random-effect logistic regression, with geographical region as the cluster unit, adjusted for baseline age, gender, 
BMI, marital status, educational level, occupation, alcohol use, hypertension, hypercholesterolemia, diabetes, self-rated health, 
smoking/vaping amount, and years of tobacco smoking.
BMultivariate random-effect linear regression, with geographical region as the cluster unit, adjusted for baseline age, gender, 
BMI, marital status, educational level, occupation, alcohol use, hypertension, hypercholesterolemia, diabetes, self-rated health, 
smoking/vaping amount, and years of tobacco smoking.
Outcomes Adjusted OR  pA
  (95% CI) 
Quitting any product (tobacco and/or e-cigarettes)
A1.  Analyses by baseline status, including the larger 12-month sample  
- Tobacco only smokers (ref. cat.) 1 (--) --
- E-cig. only users 1.25 (0.85-1.85) 0.3
- Dual users 0.98 (0.64-1.48) 0.9
  
A2. Analyses by baseline status, including only the participants 
 with 4-year follow-up data  
- Tobacco only smokers (ref. cat.) 1 (--) --
- E-cig. only users 1.22 (0.82-1.82) 0.3
- Dual users 1.03 (0.67-1.57) 0.9
  
Continuous tobacco abstinence from baseline or cessation from
 tobacco during follow-up  
A1. Analyses by baseline status, including the larger 12-month sample  
- Tobacco only smokers (ref. cat.) 1 (--) --
- E-cig. only users 5.20 (3.66-7.38) <0.001
- Dual users 1.35 (0.94-1.92) 0.10
  
A2. Analyses by baseline status, including only the participants 
 with 4-year follow-up data  
- Tobacco only smokers (ref. cat.) 1 (--) --
- E-cig. only user 5.00 (3.51-7.13) <0.001
- Dual users 1.41 (0.98-2.02) 0.066
  
Number of tobacco cig. per day - Difference 4y-baseline Adj. coefficient pb
  (95% CI)
Number of tobacco cig. per day - Difference 4y-baseline Adj. coefficient (95% CI) p B
  
A2. Analyses by baseline status, including only the participants 
 with 4-year follow-up data  
- Tobacco only smokers (ref. cat.) 0 (--) --
- Dual users 0.38 (-0.97; 1.73) 0.6
  
A3. Analyses restricted to non switchers only, with all data at 48 months  
- Tobacco only smokers (ref. cat.) 0 (--) --
- Dual users 6.80 (4.27; 9.34) <0.001
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Discussion
In this study, we have reported the results of 
the fourth year of follow-up of an observational 
cohort study evaluating the long-term safety and 
effectiveness of e-cigarettes. We were able to 
describe “real-world” vaping and smoking path-
ways over time, and to update previously pub-
lished data33,34. The main findings can be sum-
marized as follows. First, we did not observe a 
significantly lower rate of possibly smoking-re-
lated diseases (including cancers) among e-cig 
users, as compared with dual users or tobacco 
smokers. This finding was consistent across all 
analytical approaches and data sources. More-
over, e-cig use did not substantially improve 
self-reported health. On one side, these findings 
are in line with those from several other studies 
with shorter follow-up (≤2 years)4,24-27,41-44, as 
well as with the only study providing long-
term safety data (although limited to a sample 
of nine naive e-cig users)21: no serious adverse 
events and no higher risk were reported for e-cig 
when compared to traditional tobacco smoking. 
On the other side, the current results are not 
supporting the hypothesis and preliminary lab 
data suggesting a substantial harm reduction 
from e-cig exclusive use22,45-47. The interpre-
tation, however, must be cautious, since the 
excess risk of tobacco smoking may take five 
to ten years to substantially decrease48. Conse-
quently, although this is the longest follow-up 
to date, it is still insufficiently long to detect 
a significant harm reduction from e-cig among 
former smokers, as were all the participants of 
the study. Therefore, at this stage, the absence 
of a noticeable risk decrease was expected, and 
we presume that, if differences are to emerge, 
they will begin to be detectable at the last as-
sessment, which has been rescheduled from 60 
to 72 months. Second, although the complete 
switch to e-cig did seem to help tobacco quitters 
to remain abstinent from smoking, with rates 
of relapse lower than 40% after four years, the 
use of e-cig in addition to tobacco smoking 
(dual use) did not improve smoking cessation 
nor reduction: (a) baseline dual and tobacco 
smokers showed comparable quitting rates (of 
both tobacco and/or e-cig); (b) almost 80% of 
dual users relapsed to tobacco smoking alone at 
some point during the follow-up; (c) differently 
from the previous 24-month assessment34, the 
reduction of tobacco cigarettes smoked per day 
was non significantly different between dual 
users and tobacco only smokers. Expectedly, 
given the heterogeneous evidence available10,19, 
the present findings on e-cig effectiveness are 
comparable to some previous studies, report-
ing similar tobacco abstinence rates between 
dual users and tobacco smokers28,31,41,49-52, but 
different from other studies, which reported 
lower tobacco abstinence rates among e-cig us-
ers23-26,42,53,54, or showed encouraging results for 
dual use (higher quitting rates and lower relaps-
ing rates as compared to traditional smoking6,29). 
Among the suggested potential explanations34, 
the enrolment of less motivated subjects23,25,42,54, 
or previous bans against e-cigarette sales53 may 
have contributed to the low quitting rates re-
ported in some published studies. Instead, at 
least two factors have been advocated to explain 
the combined scenario of high quit rates and 
low relapse rates reported in some of the most 
recent surveys6,29: first, the free choice of e-cig 
in real-world studies may contribute to quitting 
success55; second, newer-generation e-cig may 
reduce nicotine withdrawal symptoms, thus im-
proving sustained nicotine abstinence56,57. Re-
al-life data on the pathways of use of e-cig or 
dual users are strongly needed19,22,58, as they are 
limited to two dedicated studies with one year of 
follow-up28,51. In this study, during the four years 
of follow-up, less than one fifth of the tobacco 
smokers made an attempt to use e-cig (either 
alone or in combination). In contrast, the vast 
majority of dual users and almost half of e-cig 
users changed their status at least once (and 
almost one third of both changed status twice). 
When they switched status, most dual users and 
e-cig users relapsed to tobacco smoking alone, 
mainly within the first 12 months, and only a 
minority made a further attempt to stop smok-
ing. Notably, however, once an attempt to quit 
was made, it was successful – in the following 
2 to 3 years of follow-up – in more than 60% 
of the cases. Taken together, these findings add 
to the existing evidence10,59,60 on the dramatic 
reluctance of tobacco smokers to change their 
habit over and beyond quitting, and confirm that 
the most complex step, the one requiring the 
main efforts, remains the first attempt to quit61,62. 
This study has some limitations. First, although 
false declarations were sporadic (<10 overall 
during all assessments), part of the information 
were self-reported: smoking cessation was con-
firmed with a test of carbon monoxide levels 
in only 50% of the quitters, and health data 
were checked through direct visits or hospital 
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discharge abstracts for only 62.6% of the partic-
ipants. Second, we lost 29.2% of the participants 
at the first follow-up assessment, and although 
responders and non-responders were similar for 
most variables33, and the rate of subsequent 
losses was very low, we had no 4-year data for 
almost one third of the initial sample. Third, like 
previous observational studies, we included all 
types of e-cig to approach real-life conditions, 
but different e-cig models with various nicotine 
doses might lead to diverse results28. However, 
the rates of tobacco abstinence and all-smoking 
cessation did not differ by nicotine concentra-
tion (33, 4-year data not shown), and observation-
al studies, which imply a free choice of product, 
may represent a better picture of the real world 
experiences63. Acknowledging these caveats, the 
present study provides the longest results to date 
on the comparative effectiveness of electronic 
and traditional cigarettes, in a sample of unse-
lected users, and describes for the first time the 
changes in smoking and vaping status over time 
in a real-life scenario.
Conclusions
After four years of follow-up of a large 
sample of current or former smokers, the use of 
e-cig, either alone or in combination with tobac-
co cigarettes, did not significantly decrease the 
rate of diseases potentially related to tobacco, 
and did not substantially improve self-reported 
health. Given the long-lasting health effects of 
tobacco smoking, a harm reduction from e-cig 
use, if obtainable, is expected to be detectable at 
the next follow-up assessment, which has been 
rescheduled at 72 months. Concerning e-cig 
potential effectiveness as a tool for smoking 
cessation, the complete switch to e-cig did seem 
to help tobacco quitters to remain abstinent 
from smoking, but the use of e-cig in addition 
to tobacco smoking (dual use) did not increase 
the likelihood of either smoking cessation or re-
duction. In real-life conditions, the vast majority 
of dual users and half of e-cig users switched 
smoking/vaping status during the follow-up, 
raising important issues for the classification of 
these subjects, and suggesting that real-life data, 
with multiple assessments, are required to im-
prove the validity of long-term observational or 
experimental studies on the effects of electronic 
and/or tobacco cigarettes, as well as most recent 
heat-not-burn tobacco products.
Authors’ Declaration of Personal Interests
None of the authors declare any potential conflict of in-
terests.
Declaration of Funding Interests
The first two years of the study were unfunded. The last 
two years of follow-up were funded by a research grant 
from the University of Catania and through crowdfunding 
(Kickstarter project titled “E-cigarette long-term efficacy 
and safety: a study to complete”). Besides 7 authors (MEF, 
RS, MRG, GL, MFi, PV, CM) and 7 anonymous contribu-
tors, who donated a total of €565 and €80, respectively, all 
other contributors are private citizens who had no role in 
any phase of the study. We are indebted with all of them: 
Mattia Brescianini, Necdet Yucel, Giuseppe Prosperini, 
Giancarlo Cicolini, Ludovica Rotunno, Annalisa Esposi-
to, Cristina Naccarato, Phuong Pham, Giorgio Salvatore, 
Maria Grazia D’Agati, Giacomo Manzoli, Eliseo Torrez, 
Cheng Kin Phang, Ryan White, Placido D’Agati, Fabrizio 
Bert, Macz Yaemmaneechai, Felice Iossa, Lu Gedge, Carol 
Long, Patrick Murphy, Jeff Mundine, Lucia Manzoli, Mar-
tin Smith, Julien Malfroy, Taylor Darsey, Sam Lewis, Jeff 
George, Alexander van der Wal.
Acknowledgments
The investigators are grateful to Prof. Stefano Puleo for his 
crucial support to the study funding, and to Dr. Serena Di 
Sante, Dr. Marilena Maglia, the students of the Faculty of 
Medicine of Catania and general practitioners from Abru-
zzo (Francesco Di Silvestro, Luciano Giacci, Marino Min-
cone, Gabriella Salladini, Giuliano Salvio, Renato Seller, 
Lucio Zinni) for their help during recruitment or follow-up 
assessments.
Ethics Approval
The work was approved by the Chieti-Pescara University 
Ethics Committee (Record n. 6; 25-03-2013); all partici-
pants provided written informed consent.
Registration number
NCT01785537.
References
  1) Fairchild al, lee JS, Bayer r, curran J. E-cigarettes and 
the harm-reduction continuum. N Engl J Med 2018; 
378: 216-219.
  2) Manzoli l, Boccia S. Electronic cigarettes: scarce 
data and divergent legislations. The need for evi-
dence-based health policies and research funding. 
Eur J Public Health 2015; 26: 370-371.
  3) rigotti na. Balancing the benefits and harms of 
e-cigarettes: a National Academies of Science, 
Engineering, and Medicine Report. Ann Intern Med 
2018; 168: 666-667.
F. Bravi, R. Siliquini, W. Ricciardi, P. Villari, L. Manzoli, et al.
410
  4) FarSalinoS Ke, PoulaS K, VoudriS V, le houezec J. 
Electronic cigarette use in the European Union: anal-
ysis of a representative sample of 27 460 Europeans 
from 28 countries. Addiction 2016; 111: 2032-2040.
  5) Beard e, WeSt r, Michie S, BroWn J. Association be-
tween electronic cigarette use and changes in quit 
attempts, success of quit attempts, use of smoking 
cessation pharmacotherapy, and use of stop smok-
ing services in England: time series analysis of 
population trends. BMJ 2016; 354: i4645.
  6) zhu Sh, zhuang yl, Wong S, cuMMinS Se, tedeSchi gJ. 
E-cigarette use and associated changes in popula-
tion smoking cessation: evidence from US current 
population surveys. BMJ 2017; 358: j3262.
  7) KalKhoran S, glantz Sa. E-cigarettes and smoking 
cessation in real-world and clinical settings: a sys-
tematic review and meta-analysis. Lancet Respir 
Med 2016; 4: 116-128.
  8) MalaS M, Van der teMPel J, SchWartz r, Minichiello a, 
lightFoot c, noorMohaMed a, andreWS J, zaWertailo l, 
Ferrence r. Electronic cigarettes for smoking cessa-
tion: a systematic review. Nicotine Tob Res 2016; 18: 
1926-1936.
  9) glaSSer aM, collinS l, PearSon Jl, aBudayyeh h, niaura 
rS, aBraMS dB, Villanti ac. Overview of electronic 
nicotine delivery systems: a systematic review. Am 
J Prev Med 2017; 52: e33-e66.
 10) hartMann-Boyce J, McroBBie h, Bullen c, Begh r, 
Stead lF, haJeK P. Electronic cigarettes for smoking 
cessation. Cochrane Database Syst Rev 2016; 9: 
CD010216.
 11) rahMan Ma, hann n, WilSon a, Mnatzaganian g, 
Worrall-carter l. E-cigarettes and smoking cessa-
tion: evidence from a systematic review and me-
ta-analysis. PLoS One 2015; 10: e0122544.
 12) gualano Mr, PaSSi S, Bert F, la torre g, Scaioli g, 
Siliquini r. Electronic cigarettes: assessing the effi-
cacy and the adverse effects through a systematic 
review of published studies. J Public Health (Oxf) 
2015; 37: 488-497.
 13) el diB r, SuzuMura ea, aKl ea, goMaa h, agarWal a, 
chang y, PraSad M, aShoorion V, heelS-anSdell d, MaziaK 
W, guyatt g. Electronic nicotine delivery systems and/
or electronic non-nicotine delivery systems for tobacco 
smoking cessation or reduction: a systematic review 
and meta-analysis. BMJ Open 2017; 7: e012680.
 14) McKee M, caPeWell S. Evidence about electronic ciga-
rettes: a foundation built on rock or sand? BMJ 2015; 
351: h4863.
 15) caPaSSo l, gualano Mr, Flacco Me, Siliquini r, Manzoli 
l. E-cigarette regulations in Italy: fluctuating and 
confusing. Lancet 2014; 383: 1883.
 16) McroBBie h. Modelling the population health effects of 
e-cigarettes use: current data can help guide future 
policy decisions. Nicotine Tob Res 2017; 19: 131-132.
 17) Bauld l, Mcneill a, haJeK P, Britton J, docKrell M. 
E-cigarette use in public places: striking the right 
balance. Tob Control 2017; 26: e5-e6.
 18) PiSinger c, doSSing M. A systematic review of health 
effects of electronic cigarettes. Prev Med 2014; 69: 
248-260.
 19) national acadeMieS oF ScienceS engineering and Medicine. 
Public health consequences of e-cigarettes. 
Washington, DC: The National Academies Press; 
2018.
 20) FarSalinoS K. Electronic cigarettes: an aid in smok-
ing cessation, or a new health hazard? Ther Adv 
Respir Dis 2018; 12: 1-20.
 21) PoloSa r, ciBella F, caPonnetto P, Maglia M, 
ProSPerini u, ruSSo c, taShKin d. Health impact 
of E-cigarettes: a prospective 3.5-year study of 
regular daily users who have never smoked. Sci 
Rep 2017; 7: 13825.
 22) Mcneill a, BroSe lS, calder r, Bauld l, roBSon 
d. Evidence review of e-cigarettes and heated 
tobacco products 2018. A report commissioned 
by Public Health England. London: Public Health 
England; 2018.
 23) halPern Sd, harhay Mo, SaulSgiVer K, BroPhy c, 
troxel aB, VolPP Kg. A pragmatic trial of e-ciga-
rettes, incentives and drugs for smoking cessa-
tion. N. Engl J Med 2018; 378: 2302-2310.
 20) Bullen c, hoWe c, laugeSen M, McroBBie h, Parag 
V, WilliMan J, WalKer n. Electronic cigarettes for 
smoking cessation: a randomised controlled trial. 
Lancet 2013; 382: 1629-1637.
 25) caPonnetto P, caMPagna d, ciBella F, MorJaria JB, caruSo 
M, ruSSo c, PoloSa r. EffiCiency and Safety of an 
eLectronic cigAreTte (ECLAT) as tobacco cigarettes 
substitute: a prospective 12-month randomized con-
trol design study. PLoS One 2013; 8: e66317.
 26) adriaenS K, Van gucht d, declercK P, BaeyenS F. 
Effectiveness of the electronic cigarette: an eight-
week Flemish study with six-month follow-up on 
smoking reduction, craving and experienced ben-
efits and complaints. Int J Environ Res Public 
Health 2014; 11: 11220-11248.
 27) craVo aS, BuSh J, SharMa g, SaVioz r, Martin c, 
craige S, Walele t. A randomised, parallel group 
study to evaluate the safety profile of an electron-
ic vapour product over 12 weeks. Regul Toxicol 
Pharmacol 2016; 81 Suppl 1: S1-S14.
 28) etter JF. Electronic cigarette: a longitudinal study 
of regular vapers. Nicotine Tob Res 2018; 20: 
912-922.
 29) Berry KM, reynoldS lM, collinS JM, Siegel MB, 
FetterMan Jl, haMBurg nM, Bhatnagar a, BenJaMin 
eJ, StoKeS a. E-cigarette initiation and associated 
changes in smoking cessation and reduction: the 
Population Assessment of Tobacco and Health 
Study, 2013-2015. Tob Control 2018.
 30) liu x, lu W, liao S, deng z, zhang z, liu y. 
Efficiency and adverse events of electronic cig-
arettes: A systematic review and meta-analysis 
(PRISMA-compliant article). Medicine (Baltimore) 
2018; 97: e0324.
 31) Wu Sy, Wang MP, li Wh, KWong ac, lai VW, 
laM th. Does electronic cigarette use predict 
abstinence from conventional cigarettes among 
smokers in Hong Kong? Int J Environ Res Public 
Health 2018; 15: 400-410.
 32) Manzoli l, la Vecchia c, Flacco Me, caPaSSo l, 
SiMonetti V, Boccia S, di BaldaSSarre a, Villari P, 
Mezzetti a, cicolini g. Multicentric cohort study 
on the long-term efficacy and safety of electronic 
cigarettes: study design and methodology. BMC 
Public Health 2013; 13: 883.
 33) Manzoli l, Flacco Me, Fiore M, la Vecchia c, 
Marzuillo c, gualano Mr, liguori g, cicolini g, 
caPaSSo l, d’aMario c, Boccia S, Siliquini r, ricciardi 
Cohort study of electronic cigarette use: safety and effectiveness after 4 years of follow-up
411
W, Villari P. Electronic cigarettes efficacy and 
safety at 12 months: cohort study. PLoS One 
2015; 10: e0129443.
 34) Manzoli l, Flacco Me, Ferrante M, la Vecchia c, 
Siliquini r, ricciardi W, Marzuillo c, Villari P, Fiore 
M. Cohort study of electronic cigarette use: ef-
fectiveness and safety at 24 months. Tob Control 
2017; 26: 284-292.
 35) caPPuccio F, roSSetti S, caValiere c, ioVane g, taiBi 
r, d’aniello c, iMBiMBo c, Facchini S, aBate V, 
BarBerio d, Facchini g. Health-related quality of 
life and psychosocial implications in testicular 
cancer survivors. A literature review. Eur Rev 
Med Pharmacol Sci 2018; 22: 645-661.
 36) SaVoia e, Fantini MP, PandolFi PP, dallolio l, collina 
n. Assessing the construct validity of the Italian 
version of the EQ-5D: preliminary results from a 
cross-sectional study in North Italy. Health Qual 
Life Outcomes 2006; 4: 47.
 37) hugheS Jr, PeterS en, naud S. Relapse to smok-
ing after 1 year of abstinence: a meta-analysis. 
Addict Behav 2008; 33: 1516-1520.
 38) Krall ea, garVey aJ, garcia ri. Smoking relapse 
after 2 years of abstinence: findings from the VA 
Normative Aging Study. Nicotine Tob Res 2002; 
4: 95-100.
 39) Perilli V, aceto P, ancona P, de cicco r, PaPanice d, 
Magalini S, PePe g, cozza V, gui d, lai c, Sollazzi 
l. Role of surgical setting and patients-related 
factors in predicting the occurrence of postoper-
ative pulmonary complications after abdominal 
surgery. Eur Rev Med Pharmacol Sci 2018; 22: 
547-550.
 40) yu K, Jiang zh, zhang lg. Therapeutic effects of 
long-term continuous positive airway pressure 
treatment on improving leptomeningeal collateral 
circulation in obstructive sleep apnea syndrome 
patients. Eur Rev Med Pharmacol Sci 2018; 22: 
4261-4267.
 41) PoloSa r, caPonnetto P, MorJaria JB, PaPale g, 
caMPagna d, ruSSo c. Effect of an electronic 
nicotine delivery device (e-Cigarette) on smok-
ing reduction and cessation: a prospective 
6-month pilot study. BMC Public Health 2011; 
11: 786.
 42) PoloSa r, MorJaria JB, caPonnetto P, caMPagna 
d, ruSSo c, alaMo a, aMaradio M, FiSichella 
a. Effectiveness and tolerability of electronic 
cigarette in real-life: a 24-month prospective 
observational study. Intern Emerg Med 2014; 9: 
537-546.
 43) Walele t, BuSh J, Koch a, SaVioz r, Martin c, 
o’connell g. Evaluation of the safety profile of 
an electronic vapour product used for two years 
by smokers in a real-life setting. Regul Toxicol 
Pharmacol 2018; 92: 226-238.
 44) ciBella F, caMPagna d, caPonnetto P, aMaradio 
Md, caruSo M, ruSSo c, cocKcroFt dW, PoloSa 
r. Lung function and respiratory symptoms in a 
randomized smoking cessation trial of electronic 
cigarettes. Clin Sci (Lond) 2016; 130: 1929-1937.
 45) StePhenS We. Comparing the cancer potencies of 
emissions from vapourised nicotine products in-
cluding e-cigarettes with those of tobacco smoke. 
Tob Control 2017.
 46) Pellegrino rM, tinghino B, Mangiaracina g, Marani 
a, Vitali M, Protano c, oSBorn JF, cattaruzza MS. 
Electronic cigarettes: an evaluation of exposure 
to chemicals and fine particulate matter (PM). 
Ann Ig 2012; 24: 279-288.
 47) Saitta d, choWdhury a, Ferro ga, naliS Fg, PoloSa 
r. A risk assessment matrix for public health prin-
ciples: the case for e-cigarettes. Int J Environ Res 
Public Health 2017; 14: 363.
 48) ahMed aa, Patel K, nyaKu Ma, KheirBeK re, Bittner 
V, FonaroW gc, FiliPPatoS gS, Morgan cJ, aBan iB, 
MuJiB M, deSai rV, allMan rM, White M, deedWania 
P, hoWard g, BonoW ro, Fletcher rd, aronoW WS, 
ahMed a. Risk of heart failure and death after 
prolonged smoking cessation: role of amount and 
duration of prior smoking. Circ Heart Fail 2015; 8: 
694-701.
 49) caPonnetto P, auditore r, ruSSo c, caPPello gc, 
PoloSa r. Impact of an electronic cigarette on 
smoking reduction and cessation in schizophren-
ic smokers: a prospective 12-month pilot study. Int 
J Environ Res Public Health 2013; 10: 446-461.
 50) Biener l, hargraVeS Jl. A longitudinal study of 
electronic cigarette use in a population-based 
sample of adult smokers: association with smok-
ing cessation and motivation to quit. Nicotine Tob 
Res 2014; 17: 127-133.
 51) etter JF, Bullen c. A longitudinal study of elec-
tronic cigarette users. Addict Behav 2014; 39: 
491-494.
 52) VicKerMan Ka, carPenter KM, altMan t, naSh cM, 
zBiKoWSKi SM. Use of electronic cigarettes among 
state tobacco cessation quitline callers. Nicotine 
Tob Res 2013; 15: 1787-1791.
 53) adKiSon Se, o’connor rJ, BanSal-traVerS M, hyland 
a, Borland r, yong hh, cuMMingS KM, Mcneill 
a, thraSher JF, haMMond d, Fong gt. Electronic 
nicotine delivery systems: international tobacco 
control four-country survey. Am J Prev Med 2013; 
44: 207-215.
 54) grana ra, PoPoVa l, ling PM. A longitudinal 
analysis of electronic cigarette use and smoking 
cessation. JAMA Intern Med 2014; 174: 812-813.
 55) neWton Jn, docKrell M, Marczylo t. Making sense 
of the latest evidence on electronic cigarettes. 
Lancet 2018; 391: 639-642.
 56) Bullen c. Rise in e-cigarette use linked to in-
crease in smoking cessation rates. BMJ 2017; 
358: j3506.
 57) lechner WV, Meier e, Wiener Jl, grant dM, gilMore 
J, Judah Mr, MillS ac, Wagener tl. The compar-
ative efficacy of first- versus second-generation 
electronic cigarettes in reducing symptoms of nic-
otine withdrawal. Addiction 2015; 110: 862-867.
 58) PoloSa r, caPonnetto P, niaura r, aBraMS d. Analysis 
of E-cigarette use in the 2014 Eurobarometer 
survey: calling out deficiencies in epidemiology 
methods. Intern Emerg Med 2017; 12: 733-735.
 59) hugheS Jr, Keely J, naud S. Shape of the relapse 
curve and long-term abstinence among untreated 
smokers. Addiction 2004; 99: 29-38.
 60) Stead lF, Perera r, Bullen c, Mant d, hartMann-
Boyce J, cahill K, lancaSter t. Nicotine replace-
ment therapy for smoking cessation. Cochrane 
Database Syst Rev 2012; 11: CD000146.
F. Bravi, R. Siliquini, W. Ricciardi, P. Villari, L. Manzoli, et al.
412
 61) Borland r, PartoS tr, yong hh, cuMMingS KM, 
hyland a. How much unsuccessful quitting ac-
tivity is going on among adult smokers? Data 
from the International Tobacco Control Four 
Country cohort survey. Addiction 2012; 107: 
673-682.
 62) chaiton M, dieMert l, cohen Je, Bondy SJ, SelBy P, 
PhiliPneri a, SchWartz r. Estimating the number of 
quit attempts it takes to quit smoking successfully 
in a longitudinal cohort of smokers. BMJ Open 
2016; 6: e011045.
 63) hitchMan Sc, BroSe lS, BroWn J, roBSon d, Mcneill 
a. associations between e-cigarette type, fre-
quency of use, and quitting smoking: findings 
from a longitudinal online panel survey in Great 
Britain. Nicotine Tob Res 2015; 17: 1187-1194.
